From SPF to skin color, sunscreen’s effectiveness is complicated
Summary
This episode explores the complex science and regulation of sunscreen, highlighting the FDA’s recent approval of bemotrizinol, the first new active ingredient in over 25 years. Reporter Justine Paradis discusses why SPF ratings are often misleading and examines the limitations of current testing methods. The story also addresses public health debates regarding whether blanket sunscreen advice applies to people of color, noting that the primary evidence for cancer prevention comes from a single study involving mostly white participants.
Topics discussed
Intro: Summer's last hurrah and sunscreen spotlight
Sunscreen as high-tech material and consumer expectations
History of sunscreen from Red Vet Pet to Coppertone
FDA approval of Bemotrizinol after 25 years
US regulatory hurdles and the Cares Act impact
Understanding SPF and its imperfections
Australian study reveals SPF labeling discrepancies
The importance of reapplication and usage habits
The Nambour Trial: Gold standard evidence for cancer prevention
Sunscreen efficacy and risk for people of color
Melanin as a natural shield against UV damage
Australia's new targeted sun protection guidelines
Debate over blanket advice vs. specific recommendations
Conclusion: Sunscreen as the last line of defense
Credits and sign-off
Listen ad-free on Castria